[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352585-105":59,"doc-detail-352585-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","assessing-overall-survival-benefits-in-advanced-cancers-the-role-of-external-comparator-cohort-studies-with-real-world-data","Assessing Overall Survival Benefits in Advanced Cancers - The Role of External Comparator Cohort Studies with Real-World Data","","External comparator cohort (ECC) studies with real-world data (RWD) may estimate treatment differences more reliably than single-arm trials, but can be affected by selection bias and data heterogeneity. A cross-sectional survey of healthcare professionals and international regulatory agency assessors evaluated perceived evidence strength of ECC versus SAT and randomized controlled trial (RCT) designs. Conjoint analysis quantified odds of stronger overall survival (OS) evidence ratings under scenarios varying RWD quality and OS improvements. High-quality RWD ECC showing 1.5–3-month OS gains outperformed SAT, with RCT and severe toxicity risk linked to stronger evidence.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessing-overall-survival-benefits-in-advanced-cancers-the-role-of-external-comparator-cohort-studies-with-real-world-data/352585/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessing-overall-survival-benefits-in-advanced-cancers-the-role-of-external-comparator-cohort-studies-with-real-world-data/352585.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"为什么外部对照队列（ECC）研究在晚期肿瘤中可能比单臂试验更可靠？","Question",{"text":113,"@type":114},"ECC研究结合真实世界数据（RWD），相较单臂试验缺乏并行对照的问题，可能提供更可靠的治疗差异估计。然而仍可能受选择偏倚和数据异质性影响。","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"本研究如何评估不同研究设计的证据强度感知？",{"text":118,"@type":114},"研究对来自欧洲血液学会、欧洲肿瘤内科学会的医疗专业人员以及国际监管机构评估人员开展横断面调查，并使用联合分析在不同情景下对总体生存（OS）效果的证据强度进行评分。",{"name":120,"@type":111,"acceptedAnswer":121},"高质量RWD的ECC研究在OS获益证据上与单臂试验相比结果如何？",{"text":122,"@type":114},"相较于显示1.5个月与3个月OS改善但基于较弱比较方式的SAT，高质量RWD ECC研究对应获得更高证据强度评级的优势更大。文中同时指出，证据强度评级与可接受的严重或症状性毒性风险相关。",{"name":124,"@type":111,"acceptedAnswer":125},"研究结论对临床药理学或转化科学意味着什么？",{"text":126,"@type":114},"尽管随机对照试验仍是金标准，高质量RWD支持的ECC研究可在评估晚期肿瘤OS获益方面发挥补充作用，并可能被认为比单臂试验更有说服力，从而用于支持监管与临床决策。","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},352585,1790507032,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":46,"preview_page_count":19,"preview_urls":149},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data  \nFrancesco Pignatti 1,*  , Tarec Christoffer El-Galaly2  , Martin Kaiser3  , Kimmo Porkka4  ,  \nRobin Doeswijk5  , Peter Mol6,7  , Donna R. Rivera8  , Catherine C. Lerro8  , Ulrich-Peter Rohr9  , Patrice Verpillat1  , Antonios Valachis 10  , Dario Trapani 11,12  , Massimo DiMaio 13  , Nicola Latino 14  , Raul Cordoba 15  , Nathan Cherny16  , Miriam Koopman 17  , Diogo Martins-Branco 14  ,  \nGeorge Pentheroudakis 14  and Douwe Postmus6   \nExternal comparator cohort (ECC) studies with real-world data (RWD) may provide more reliable estimates of treatment differences compared to single-arm trials (SAT), yet they face limitations such as selection bias and data heterogeneity. This study assessed the perceived strength of evidence of ECC studies compared to SAT and randomized controlled studies (RCT). The study included healthcare professionals (HCP) from the European Hematology Association (EHA), the European Society for Medical Oncology (ESMO), and assessors from international regulatory agencies (RA). A conjoint analysis evaluated strength of evidence ratings for establishing an effect on OS for different hypothetical scenarios, based on different designs, RWD quality, and observed OS improvement, for a new cancer treatment for advanced disease and no effective treatments. Participants from HCP organizations rated RWD studies favorably (advantages outweigh disadvantages) more frequently (47.6%; n = 103) compared to RA participants (12.9%; n = 116). Compared to a SAT, a highquality RWD ECC study showing a 1.5-month and 3-month OS improvement had 2.7 (95% CI: 1.9–3.8) and 14.7 (95% CI:  \n10.0–21.5) times higher odds of receiving a higher strength of evidence rating, respectively. The OR for RCT v. SAT was  \n36.4 (95% CI: 24.0–55.2) and 358.4 (95% CI: 217.3–591.3), respectively. Strength of evidence ratings were associated with maximum acceptable risk of severe or symptomatic toxicity. In conclusion, when evaluating the OS of new therapies, ECC studies with RWD, especially when based on high-quality RWD or demonstrating a larger OS benefit, were rated as more convincing than SAT without a formal control.  \nStudy Highlights  \nWHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  \n; Non-randomized, single-arm trials lack concurrent comparators, leading to challenges in reliably assessing overall survival outcomes. External comparator cohort studies maybe used, aiming to provide more reliable efficacy estimates. However, these studies also present limitations, including potential selection bias and data quality. As a result, the role of external comparator cohort studies in informing clinical and regulatory decisions remains a topic of ongoing debate.  \nWHAT QUESTION DID THIS STUDY ADDRESS?  \n; This study used a cross-sectional survey with healthcare professionals and regulatory agency assessors to describe the perceived strength of evidence of comparator cohort studies, compared to single-arm trials and randomized controlled trials. Attitudes about these methodologies, and concerns  \nsuch as lack of randomization and data quality, were also described.  \nWHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?  \n; A high-quality real-world data external comparator cohort study showing a 1.5-month to 3-month overall survival improvement had higher odds of being rated as stronger evidence compared to a single-arm trial with informal comparison to the literature. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?  \n; While randomized controlled trials remain the gold standard, external comparator cohort studies using high-quality real-world data can play a complementary role in assessing overall survival benefits in advanced cancers, providing evidence that is perceived to be stronger than single-arm trials alone, to inform regulatory and clinical decisions.  \nReceived November 8, 2025; accepted December 30, 2025. doi","cbCaiu4odsuFAOG4","https://ap.wps.com/l/cbCaiu4odsuFAOG4","pdf",1338449,"English","# Study Background\n## Limitations of Single-Arm Trials and ECC Studies\n# Research Question and Methods\n## Cross-Sectional Survey and Conjoint Analysis\n# Key Findings\n## Comparative Evidence Ratings for OS\n## Effects of RWD Quality and OS Benefit\n# Study Highlights\n## Current Knowledge\n## Question Addressed\n## Added Value and Impact\n# Implications and Conclusion","[{\"question\":\"为什么外部对照队列（ECC）研究在晚期肿瘤中可能比单臂试验更可靠？\",\"answer\":\"ECC研究结合真实世界数据（RWD），相较单臂试验缺乏并行对照的问题，可能提供更可靠的治疗差异估计。然而仍可能受选择偏倚和数据异质性影响。\"},{\"question\":\"本研究如何评估不同研究设计的证据强度感知？\",\"answer\":\"研究对来自欧洲血液学会、欧洲肿瘤内科学会的医疗专业人员以及国际监管机构评估人员开展横断面调查，并使用联合分析在不同情景下对总体生存（OS）效果的证据强度进行评分。\"},{\"question\":\"高质量RWD的ECC研究在OS获益证据上与单臂试验相比结果如何？\",\"answer\":\"相较于显示1.5个月与3个月OS改善但基于较弱比较方式的SAT，高质量RWD ECC研究对应获得更高证据强度评级的优势更大。文中同时指出，证据强度评级与可接受的严重或症状性毒性风险相关。\"},{\"question\":\"研究结论对临床药理学或转化科学意味着什么？\",\"answer\":\"尽管随机对照试验仍是金标准，高质量RWD支持的ECC研究可在评估晚期肿瘤OS获益方面发挥补充作用，并可能被认为比单臂试验更有说服力，从而用于支持监管与临床决策。\"}]","Assessing Overall Survival Benefits in Advanced Cancers - The Role of External Comparator Cohort Studies with Real-World Data | PDF",1790100340,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41d7aa3e923e3f80625902a7215171f4.webp",983,1296,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9bd6500790c03a0b19ed33c2c665e07.webp",982,1294,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a18108d868c8acd80565630b8ffe5944.webp",981,1293,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b598fa9820c9014c9da5a8bc71bb50e1.webp",980,1292]